Safety Study of Single Administration Intravenous Treatment for Influenza
A Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of AVI-7100 in Healthy Subjects
Sponsor: Sarepta Therapeutics, Inc.
Terminated
The study was halted after enrollment of the first cohort because of lack of funding
Other terminated trials from Sarepta Therapeutics, Inc.
- Duchenne Muscular Dystrophy · Phase PHASE1 · Aug 2025
- Limb Girdle Muscular Dystrophy · Phase PHASE1 · Jun 2025
- Limb Girdle Muscular Dystrophy · Phase PHASE1 · Jun 2025
- Duchenne Muscular Dystrophy · Phase PHASE2 · Feb 2025
- Limb-Girdle Muscular Dystrophy, Type 2E · Phase PHASE1/PHASE2 · Jan 2025
More terminations from Sarepta Therapeutics, Inc.
Other Influenza trials with similar outcome
Listed as NCT01375985, this PHASE1 trial focuses on Influenza and remains terminated or withdrawn. Sponsored by Sarepta Therapeutics, Inc., it has been updated 7 times since 2011, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Aug 2019 — Jan 2021 [monthly]
Terminated PHASE1
-
Jun 2018 — Aug 2019 [monthly]
Terminated PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Jun 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sarepta Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .